Skip to main content
Equibles
LIMN logo

LIMN · Liminatus Pharma, Inc. · Metrics

Track LIMN — free

Use LIMN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research LIMN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.82 -0.08 (-2.59%) At close · Oct 30
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“In connection with the Company's assessment of going concern considerations in accordance with Financial Accounting Standards Board ("FASB") ASC 205-40, Presentation of Financial Statements—Going Concern, management has concluded that there is substantial doubt about its ability to continue as a going concern for one year after the date that the accompanying unaudited condensed consolidated financial statements are issued.”
View the 10-Q filed Aug 14, 2026
Market Cap
$3.79M
Shares
1.34M
Volume · Oct 30 12.98K Avg daily vol (50 sessions) 31.68K

LIMN metrics

48 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.82
Market cap
$3.79M

Price action

20 metrics
Price change (1W)
-4.1%
Price change (30D)
-27.7%
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
—
Annualized volatility (3M)
—
Beta
—
RSI (14D)
32.5
Price vs SMA 50
-22.9%
Price vs SMA 200
—
Avg volume (3M)
31,676
Relative volume
0.4
Average dollar volume
$121,967

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
1.34M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
12.6
reciprocal yield 7.9%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-330.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$4.07M
Net income (TTM)
−$12.52M
Trailing 12 months
Diluted EPS (TTM)
$-23.50
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-5.89
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-21.48
Operating cash flow per diluted share (TTM)
$-5.63
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-18.13

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
-1,342.2%
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+107.7%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-4,165.9%
Return on assets
-367.9%
Debt / equity
4.8
Current ratio
1.1
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
1.1
Interest coverage
-53.8
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$19.97M
Latest balance sheet
Cash & equivalents
$0
Total assets
$3.40M
Total debt
$1.44M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$3.97M
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
36
13F filer change QoQ
+1
Institutional ownership
3.9%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
1.4%
Private-fund adviser ownership
0.9%
Active holders' share change QoQ
-45.7%
Holder tenure
2.3
Price vs estimated holder cost
-92.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.2%

Short interest

3 metrics
Short interest
3.0%
Latest settlement · 1.8 days to cover
Days to cover
1.8d
Short-squeeze score
40 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1971387 CUSIP 53271X207 Visit website